A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Asthenia
- Focus Therapeutic Use
- Sponsors Longeveron
- 11 Jul 2017 Status changed from not yet recruiting to recruiting.
- 21 Jun 2017 Planned initiation date changed from 19 Jun 2017 to 30 Jul 2017.
- 01 Jun 2017 Planned initiation date changed from 30 May 2017 to 19 Jun 2017.